PRA recently performed a feasibility study to identify investigators who see patients with a rare neuromuscular autoimmune disease and who have the capability to perform a Phase II clinical trial. It was estimated that there may only be 1,000 to 3,000 patients in the US and Europe with the condition. By identifying 88 interested investigators and areas of high prevalence during the feasibility study, PRA and the sponsor developed a unique, data-based strategy for the clinical program.
Complex Feasibility Assessment in Low- & Middle-Income Countries
Complex Feasibility Assessment in Low- & Middle-Income Countries.
Overcoming Recruitment Challenges to Meet Vaccine Study Enrollment
Through an enhanced enrollment plan, PRA helped a client meet challenging enrollment goals in a vaccine study. Our innovative strategies contributed…
PRA Exceeds Tough Enrollment Goals
A Phase IIb, double-blind, randomized, parallel-group, placebo-controlled study to evaluate the safety, tolerability and efficacy of Study Drug in…